MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Japan accepts GSK application for expanded use of RSV vaccine Arexvy

ALN

GSK PLC on Friday announced that Japan has accepted a regulatory application to expand the use of its respiratory syncytial virus [RSV] vaccine Arexvy.

The London-based pharmaceutical company said Japan’s Ministry of Health, Labour & Welfare accepted the regulatory application to expand use of the vaccine in adults aged 18 to 49 who are at increased risk of severe RSV.

The application is supported by positive results from a phase 3B data which showed a non-inferior immune response in adults aged 18 to 49 at increased risk for RSV-lower respiratory tract disease due to some underlying medical conditions, to that observed in adults aged 60 and over.

GSK said it is the first company to seek regulatory approval for the vaccine for 18-49 year olds at increased risk of RSV disease in Japan.

GSK shares were flat at 1,435.00 pence each on Friday morning in London, giving it a market capitalisation of £58.74 billion.

Copyright 2025 Alliance News Ltd. All Rights Reserved.